Nonetheless, our work primarily tested a PARylation inhibitor, and future studies will be needed to evaluate whether PARP‐trapping inhibitors elicit similar or even stronger resistance mechanisms in IDH‐mutant gliomas. This evidence concerns the gene IDH1 and central nervous system cancer.